Targeting B7x and B7-H3 as New Immunotherapies for Prostate Cancer

Abstract

We have made excellent progress during the three-year funding period, as evidenced by eight publications. We have shown the mechanisms by which B7x inhibits T cell function and promotes prostate cancer progress. We have solved structure of B7xIgV function domain and developed new mAbs to the IgV domain for a new cancer immunotherapy targeting B7x. Similarly, we developed new mAbs to the IgV domain of B7-H3 and are in the process of developing new cancer immunotherapy targetingB7-H3. We have discovered HHLA2 and TMIGD2 as the newest members of the B7-CD28 immune checkpoint family and further showed HHLA2 was highly expressed in human prostate cancer, which provided a potential new therapeutic target for human prostate cancer and other cancers as well.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Nov 01, 2017
Accession Number
AD1047120

Entities

People

  • Xingxing Zang

Organizations

  • Albert Einstein College of Medicine

Tags

DTIC Thesaurus Topics

  • Cell Physiological Processes
  • Cells
  • Chemical Synthesis
  • Chemistry
  • Health Services
  • Lymphocytes
  • Medical Personnel
  • Oncology

Fields of Study

  • Biology

Readers

  • Molecular Biology and Genetics
  • Oncology (Cancer Research).

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech